Arcturus Therapeutics (ARCT) Tops Q3 EPS by $1.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold—if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
November 14, 2023 4:01 PM ESTExpected cash runway extended to the end of 2026
$35 million milestone achieved under CSL collaboration
ARCT-154 remains on track for Japan-NDA approval in December
Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial
Enrollment initiated in ARCT-032 Phase 1b study; dosing first cystic fibrosis patient this month
ARCT-032 received Rare Pediatric Disease Designation for cystic fibrosis from the FDA
Investor conference call at 4:30 p.m. ET November 14, 2023
SAN DIEGO--(BUSINESS WIRE)-- Arcturus... More
